LOS ANGELES, July 13, 2018 (GLOBE NEWSWIRE) — Capricor Therapeutics (NASDAQ:CAPR) and Parent Project Muscular Dystrophy (PPMD) will host a webinar at 1 p.m. ET on July 18 to provide information about the HOPE-2 clinical trial, which is evaluating the safety and efficacy of repeat doses of CAP-1002 in boys and young men with Duchenne muscular dystrophy and reduced upper limb function.
HOPE-2 is a Phase II, randomized, double-blind, placebo-controlled clinical trial that will randomize up to 84 participants at approximately 10-15 medical centers in the United States.
An earlier clinical trial, HOPE-Duchenne, found a single intracoronary dose of CAP-1002 in participants in advanced stages of Duchenne muscular dystrophy was generally safe and well tolerated. The trial also found significant and sustained improvement in cardiac and skeletal muscle function among those receiving CAP-1002 when compared to participants who received usual care only.
“Please join PPMD and Capricor as we host this webinar to provide a brief background of CAP-1002 and its clinical development leading up to this exciting clinical trial,” said Linda Marbán, Ph.D., Capricor chief executive officer. “We will review the design of the HOPE-2 trial, eligibility criteria and assessments that participants will need to complete to participate in the trial.”
Capricor and PPMD Webinar
Date: Wednesday, July 18, 2018
Time: 1-2 p.m. ET
Connect via the web: www.readytalk.com, access code: 9449985
Connect via phone: 866.740.1260, access code: 9449985
- Linda Marban, Ph.D., Capricor chief executive officer
- Pat Furlong, PPMD president
- Craig M. McDonald, M.D., HOPE-2 principal investigator and professor of pediatrics at the University of California, Davis
- Deborah Ascheim, M.D., Capricor chief medical officer
For more information on HOPE-2, please visit www.HOPE2Trial.com.
About Duchenne Muscular Dystrophy
Duchenne muscular dystrophy is a devastating genetic disorder that causes muscle degeneration and leads to death, generally before the age of 30, most commonly from heart failure. It occurs in one in every 3,600 live male births across all races, cultures and countries. Duchenne muscular dystrophy afflicts approximately 200,000 boys and young men around the world. Treatment options are limited, and there is no cure.
CAP-1002 consists of allogeneic cardiosphere-derived cells, or CDCs, a unique population of cells that contains cardiac progenitor cells. CAP-1002 has been shown to exert potent immunomodulatory activity and stimulate cellular regeneration. CDCs have been the subject of over 100 peer-reviewed scientific publications and have been administered to approximately 140 human subjects across several clinical trials.
About Capricor Therapeutics
Capricor Therapeutics, Inc. (NASDAQ:CAPR) is a clinical-stage biotechnology company focused on the discovery, development and commercialization of first-in-class biological therapeutics for the treatment of rare disorders. Capricor’s lead candidate, CAP-1002, is an allogeneic cell therapy that is currently in clinical development for the treatment of Duchenne muscular dystrophy. Capricor has also established itself as one of the leading companies investigating the field of extracellular vesicles and is exploring the potential of CAP-2003, a cell-free, exosome-based candidate, to treat a variety of disorders. For more information, please visit www.capricor.com.
About Parent Project Muscular Dystrophy
Parent Project Muscular Dystrophy (PPMD) is the largest most comprehensive nonprofit organization in the United States focused on finding a cure for Duchenne muscular dystrophy—its mission is to end Duchenne.
PPMD invests deeply in treatments for this generation of people affected by Duchenne and in research that will benefit future generations. It advocates in Washington, D.C., and has secured hundreds of millions of dollars in funding. PPMD demands optimal care, and it strengthens, unites and educates the global Duchenne community.
Everything PPMD does—and everything it has done since its founding in 1994—helps people with Duchenne live longer, stronger lives. PPMD will not rest until every person has a treatment to end Duchenne. Go to www.ParentProjectMD.org for more information or to learn how to support its efforts and help families affected by Duchenne. Follow PPMD on Facebook, Twitter and YouTube.
Cautionary Note Regarding Forward-Looking Statements
Statements in this press release regarding the efficacy, safety, and intended utilization of Capricor’s product candidates; the initiation, conduct, size, timing and results of discovery efforts and clinical trials; the pace of enrollment of clinical trials; plans regarding regulatory filings, future research and clinical trials; regulatory developments involving products, including the ability to obtain regulatory approvals or otherwise bring products to market; plans regarding current and future collaborative activities and the ownership of commercial rights; scope, duration, validity and enforceability of intellectual property rights; future royalty streams, expectations with respect to the expected use of proceeds from the recently completed offerings and the anticipated effects of the offerings, and any other statements about Capricor’s management team’s future expectations, beliefs, goals, plans or prospects constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Any statements that are not statements of historical fact (including statements containing the words “believes,” “plans,” “could,” “anticipates,” “expects,” “estimates,” “should,” “target,” “will,” “would” and similar expressions) should also be considered to be forward-looking statements. There are a number of important factors that could cause actual results or events to differ materially from those indicated by such forward-looking statements. More information about these and other risks that may impact Capricor’s business is set forth in Capricor’s Annual Report on Form 10-K for the year ended December 31, 2017 as filed with the Securities and Exchange Commission on March 22, 2018, in its Registration Statement on Form S-3, as filed with the Securities and Exchange Commission on September 28, 2015, together with the prospectus included therein and prospectus supplements thereto and in its Quarterly Report on Form 10-Q for the quarter ended March 31, 2018, as filed with the Securities and Exchange Commission on May 14, 2018. All forward-looking statements in this press release are based on information available to Capricor as of the date hereof, and Capricor assumes no obligation to update these forward-looking statements.
CAP-1002 is an Investigational New Drug and is not approved for any indications. CAP-2003 has not yet been approved for clinical investigation.
For more information, please contact: AJ Bergmann, Chief Financial Officer +1-310-358-3200 firstname.lastname@example.org